M0300 – Iv chelation therapy (chemical endarterectomy)

Long description

Iv chelation therapy (chemical endarterectomy)

Short description

Iv chelationtherapy

Pricing indicator

00 Not separately priced by Part B (bundled, not covered or Part A only)

Medicare coverage

M Non-covered by Medicare

BETOS category

Y2 Other - Non-Medicare fee schedule

Added

January 1, 1986

Last change

January 1, 1996 – No change

Nearby M codes

• M0243 – Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
• M0244 – Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0245 – Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
• M0246 – Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the covid 19 public health emergency
• M0247 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
• M0248 – Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
• M0249 – Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
• M0250 – Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose
• M0301 – Fabric wrapping of abdominal aneurysm
• M1000 – Pain screened as moderate to severe
• M1001 – Plan of care to address moderate to severe pain documented on or before the date of the second visit with a clinician
• M1002 – Plan of care for moderate to severe pain not documented on or before the date of the second visit with a clinician, reason not given
• M1003 – Tb screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy
• M1004 – Documentation of medical reason for not screening for tb or interpreting results (i.e., patient positive for tb and documentation of past treatment; patient who has recently completed a course of anti-tb therapy)
• M1005 – Tb screening not performed or results not interpreted, reason not given
• M1006 – Disease activity not assessed, reason not given